vs
Side-by-side financial comparison of Cellectis S.A. (CLLS) and Crexendo, Inc. (CXDO). Click either name above to swap in a different company.
Crexendo, Inc. is the larger business by last-quarter revenue ($18.1M vs $9.5M, roughly 1.9× Cellectis S.A.). Crexendo, Inc. runs the higher net margin — 6.7% vs -265.9%, a 272.6% gap on every dollar of revenue. On growth, Cellectis S.A. posted the faster year-over-year revenue change (375.0% vs 11.2%).
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
Crexendo, Inc. is a U.S.-headquartered cloud communications technology provider. It delivers unified communications as a service (UCaaS), contact center solutions, business VoIP services, and collaborative work tools, primarily catering to small and medium-sized enterprises operating in the North American market.
CLLS vs CXDO — Head-to-Head
Income Statement — Q2 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $18.1M |
| Net Profit | $-25.3M | $1.2M |
| Gross Margin | — | — |
| Operating Margin | -181.1% | 6.3% |
| Net Margin | -265.9% | 6.7% |
| Revenue YoY | 375.0% | 11.2% |
| Net Profit YoY | -51.9% | 140.2% |
| EPS (diluted) | $-0.28 | $0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $18.1M | ||
| Q3 25 | — | $17.5M | ||
| Q2 25 | — | $16.6M | ||
| Q1 25 | — | $16.1M | ||
| Q4 24 | — | $16.2M | ||
| Q3 24 | — | $15.6M | ||
| Q2 24 | $9.5M | $14.7M | ||
| Q1 24 | — | $14.3M |
| Q4 25 | — | $1.2M | ||
| Q3 25 | — | $1.4M | ||
| Q2 25 | — | $1.2M | ||
| Q1 25 | — | $1.2M | ||
| Q4 24 | — | $507.0K | ||
| Q3 24 | — | $148.0K | ||
| Q2 24 | $-25.3M | $588.0K | ||
| Q1 24 | — | $434.0K |
| Q4 25 | — | 6.3% | ||
| Q3 25 | — | 7.5% | ||
| Q2 25 | — | 6.7% | ||
| Q1 25 | — | 7.2% | ||
| Q4 24 | — | 3.9% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | -181.1% | 3.9% | ||
| Q1 24 | — | 3.4% |
| Q4 25 | — | 6.7% | ||
| Q3 25 | — | 8.3% | ||
| Q2 25 | — | 7.4% | ||
| Q1 25 | — | 7.3% | ||
| Q4 24 | — | 3.1% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | -265.9% | 4.0% | ||
| Q1 24 | — | 3.0% |
| Q4 25 | — | $0.03 | ||
| Q3 25 | — | $0.05 | ||
| Q2 25 | — | $0.04 | ||
| Q1 25 | — | $0.04 | ||
| Q4 24 | — | $0.03 | ||
| Q3 24 | — | $0.00 | ||
| Q2 24 | $-0.28 | $0.02 | ||
| Q1 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $149.0M | — |
| Total DebtLower is stronger | — | $114.0K |
| Stockholders' EquityBook value | $148.6M | $63.8M |
| Total Assets | $407.1M | $77.7M |
| Debt / EquityLower = less leverage | — | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $149.0M | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $114.0K | ||
| Q3 25 | — | $236.0K | ||
| Q2 25 | — | $356.0K | ||
| Q1 25 | — | $475.0K | ||
| Q4 24 | — | $592.0K | ||
| Q3 24 | — | $709.0K | ||
| Q2 24 | — | $823.0K | ||
| Q1 24 | — | $937.0K |
| Q4 25 | — | $63.8M | ||
| Q3 25 | — | $61.3M | ||
| Q2 25 | — | $58.3M | ||
| Q1 25 | — | $55.2M | ||
| Q4 24 | — | $51.4M | ||
| Q3 24 | — | $49.5M | ||
| Q2 24 | $148.6M | $48.2M | ||
| Q1 24 | — | $46.8M |
| Q4 25 | — | $77.7M | ||
| Q3 25 | — | $76.0M | ||
| Q2 25 | — | $71.4M | ||
| Q1 25 | — | $67.4M | ||
| Q4 24 | — | $64.9M | ||
| Q3 24 | — | $62.3M | ||
| Q2 24 | $407.1M | $59.6M | ||
| Q1 24 | — | $57.5M |
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.01× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | — | 0.01× | ||
| Q3 24 | — | 0.01× | ||
| Q2 24 | — | 0.02× | ||
| Q1 24 | — | 0.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.9M | $2.3M |
| Free Cash FlowOCF − Capex | $27.6M | — |
| FCF MarginFCF / Revenue | 290.5% | — |
| Capex IntensityCapex / Revenue | 13.2% | 0.0% |
| Cash ConversionOCF / Net Profit | — | 1.93× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.3M | ||
| Q3 25 | — | $4.4M | ||
| Q2 25 | — | $1.3M | ||
| Q1 25 | — | $1.2M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | — | $1.6M | ||
| Q2 24 | $28.9M | $2.7M | ||
| Q1 24 | — | $-166.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $1.3M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $2.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | $27.6M | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 7.7% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | 290.5% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | 13.2% | 0.0% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | 1.93× | ||
| Q3 25 | — | 3.05× | ||
| Q2 25 | — | 1.05× | ||
| Q1 25 | — | 1.06× | ||
| Q4 24 | — | 4.29× | ||
| Q3 24 | — | 10.95× | ||
| Q2 24 | — | 4.51× | ||
| Q1 24 | — | -0.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLLS
Segment breakdown not available.
CXDO
| Services | $8.6M | 48% |
| Software Solution Segment | $8.3M | 46% |
| Products | $1.1M | 6% |
